The role of β-adrenergic receptor signaling in the proliferation of hemangioma-derived endothelial cells

Cell Division

Volumn 8, Issue 1, 2013, Pages

  Ji, Yi ^a   Chen, Siyuan ^a   Li, Kai ^a   Xiao, Xianmin ^a   Zheng, Shan ^a   Xu, Ting ^a  

^a CHILDREN S HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

Cell cycle; Endothelial cells; Infantile hemangioma; Proliferation

Indexed keywords

EID: 84871721459     PISSN: None     EISSN: 17471028     Source Type: Journal    
DOI: 10.1186/1747-1028-8-1     Document Type: Article

References (57)

1. Drolet BA, Esterly NB, Frieden IJ. Hemangiomas in children. N Engl J Med 1999, 341(3):173-181. 10.1056/NEJM199907153410307, 10403856.
2. Mulliken JB, Fishman SJ, Burrows PE. Vascular anomalies. Curr Probl Surg 2000, 37(8):517-584. 10.1016/S0011-3840(00)80013-1, 10955029.
3. Drolet BA, Swanson EA, Frieden IJ. Infantile hemangiomas: an emerging health issue linked to an increased rate of low birth weight infants. J Pediatr 2008, 153(5):712-715. 711-715, 10.1016/j.jpeds.2008.05.043, 18940356.
4. Frieden IJ, Haggstrom AN, Drolet BA, Mancini AJ, Friedlander SF, Boon L, Chamlin SL, Baselga E, Garzon MC, Nopper AJ, et al. Infantile hemangiomas: current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas, April 7-9, 2005, Bethesda, Maryland, USA. Pediatr Dermatol 2005, 22(5):383-406. 10.1111/j.1525-1470.2005.00102.x, 16190987.
5. Takahashi K, Mulliken JB, Kozakewich HP, Rogers RA, Folkman J, Ezekowitz RA. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 1994, 93(6):2357-2364. 10.1172/JCI117241, 294441, 7911127.
6. Tan ST, Velickovic M, Ruger BM, Davis PF. Cellular and extracellular markers of hemangioma. Plast Reconstr Surg 2000, 106(3):529-538.
7. Greenberger S, Boscolo E, Adini I, Mulliken JB, Bischoff J. Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells. N Engl J Med 2010, 362(11):1005-1013. 10.1056/NEJMoa0903036, 2845924, 20237346.
8. Boye E, Yu Y, Paranya G, Mulliken JB, Olsen BR, Bischoff J. Clonality and altered behavior of endothelial cells from hemangiomas. J Clin Invest 2001, 107(6):745-752. 10.1172/JCI11432, 208946, 11254674.
9. Jinnin M, Medici D, Park L, Limaye N, Liu Y, Boscolo E, Bischoff J, Vikkula M, Boye E, Olsen BR. Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nat Med 2008, 14(11):1236-1246. 10.1038/nm.1877, 2593632, 18931684.
10. George ME, Sharma V, Jacobson J, Simon S, Nopper AJ. Adverse effects of systemic glucocorticosteroid therapy in infants with hemangiomas. Arch Dermatol 2004, 140(8):963-969. 10.1001/archderm.140.8.963, 15313812.
11. Goyal R, Watts P, Lane CM, Beck L, Gregory JW. Adrenal suppression and failure to thrive after steroid injections for periocular hemangioma. Ophthalmology 2004, 111(2):389-395. 10.1016/S0161-6420(03)00833-9, 15019396.
12. Chang LC, Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, Horii KA, Lucky AW, Mancini AJ, Metry DW, et al. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics 2008, 122(2):360-367. 10.1542/peds.2007-2767, 18676554.
13. Leaute-Labreze C, Dumas DLRE, Hubiche T, Boralevi F, Thambo JB, Taieb A. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008, 358(24):2649-2651. 10.1056/NEJMc0708819, 18550886.
14. Sans V, de la Roque ED, Berge J, Grenier N, Boralevi F, Mazereeuw-Hautier J, Lipsker D, Dupuis E, Ezzedine K, Vergnes P, et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics 2009, 124(3):e423-e431. 10.1542/peds.2008-3458, 19706583.
15. Leboulanger N, Fayoux P, Teissier N, Cox A, Van Den Abbeele T, Carrabin L, Couloigner V, Nicollas R, Triglia JM, Ayari S, et al. Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma: a preliminary retrospective study of French experience. Int J Pediatr Otorhinolaryngol 2010, 74(11):1254-1257. 10.1016/j.ijporl.2010.07.025, 20800295.
16. Manunza F, Syed S, Laguda B, Linward J, Kennedy H, Gholam K, Glover M, Giardini A, Harper JI. Propranolol for complicated infantile haemangiomas: a case series of 30 infants. Br J Dermatol 2010, 162(2):466-468. 10.1111/j.1365-2133.2009.09597.x, 20055816.
17. Truong MT, Chang KW, Berk DR, Heerema-McKenney A, Bruckner AL. Propranolol for the treatment of a life-threatening subglottic and mediastinal infantile hemangioma. J Pediatr 2010, 156(2):335-338. 10.1016/j.jpeds.2009.10.010, 20105647.
18. Fuchsmann C, Quintal MC, Giguere C, Ayari-Khalfallah S, Guibaud L, Powell J, McCone C, Froehlich P. Propranolol as first-line treatment of head and neck hemangiomas. Arch Otolaryngol Head Neck Surg 2011, 137(5):471-478. 10.1001/archoto.2011.55, 21576558.
19. Hogeling M, Adams S, Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics 2011, 128(2):e259-e266. 10.1542/peds.2010-0029, 21788220.
20. Schupp CJ, Kleber JB, Gunther P, Holland-Cunz S. Propranolol therapy in 55 infants with infantile hemangioma: dosage, duration, adverse effects, and outcome. Pediatr Dermatol 2011, 28(6):640-644. 10.1111/j.1525-1470.2011.01569.x, 21995836.
21. Hong E, Fischer G. Propranolol for recalcitrant ulcerated hemangioma of infancy. Pediatr Dermatol 2012, 29(1):64-67. 10.1111/j.1525-1470.2011.01547.x, 21854419.
22. Anitole-Misleh KG, Brown KM. Developmental regulation of catecholamine levels during sea urchin embryo morphogenesis. Comp Biochem Physiol A Mol Integr Physiol 2004, 137(1):39-50. 10.1016/j.cbpb.2003.09.001, 14720589.
23. Kim MO, Na SI, Lee MY, Heo JS, Han HJ. Epinephrine increases DNA synthesis via ERK1/2 s through cAMP, Ca(2+)/PKC, and PI3K/Akt signaling pathways in mouse embryonic stem cells. J Cell Biochem 2008, 104(4):1407-1420. 10.1002/jcb.21716, 18275042.
24. Herlenius E, Lagercrantz H. Neurotransmitters and neuromodulators during early human development. Early Hum Dev 2001, 65(1):21-37. 10.1016/S0378-3782(01)00189-X, 11520626.
25. Iaccarino G, Ciccarelli M, Sorriento D, Galasso G, Campanile A, Santulli G, Cipolletta E, Cerullo V, Cimini V, Altobelli GG, et al. Ischemic neoangiogenesis enhanced by beta2-adrenergic receptor overexpression: a novel role for the endothelial adrenergic system. Circ Res 2005, 97(11):1182-1189. 10.1161/01.RES.0000191541.06788.bb, 16239589.
26. Lutgendorf SK, Cole S, Costanzo E, Bradley S, Coffin J, Jabbari S, Rainwater K, Ritchie JM, Yang M, Sood AK. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res 2003, 9(12):4514-4521.
27. Lai KB, Sanderson JE, Yu CM. The regulatory effect of norepinephrine on connective tissue growth factor (CTGF) and vascular endothelial growth factor (VEGF) expression in cultured cardiac fibroblasts. Int J Cardiol 2011, In press.
28. Schuller HM. Beta-adrenergic signaling, a novel target for cancer therapy?. Oncotarget 2010, 1(7):466-469. 3248132, 21317444.
29. Lamy S, Lachambre MP, Lord-Dufour S, Beliveau R. Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells. Vascul Pharmacol 2010, 53(5-6):200-208.
30. Takahashi T, Ueno H, Shibuya M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 1999, 18(13):2221-2230. 10.1038/sj.onc.1202527, 10327068.
31. Liu X, Wu WK, Yu L, Sung JJ, Srivastava G, Zhang ST, Cho CH. Epinephrine stimulates esophageal squamous-cell carcinoma cell proliferation via beta-adrenoceptor-dependent transactivation of extracellular signal-regulated kinase/cyclooxygenase-2 pathway. J Cell Biochem 2008, 105(1):53-60. 10.1002/jcb.21802, 18452159.
32. Guo Y, Yang K, Harwalkar J, Nye JM, Mason DR, Garrett MD, Hitomi M, Stacey DW. Phosphorylation of cyclin D1 at Thr 286 during S phase leads to its proteasomal degradation and allows efficient DNA synthesis. Oncogene 2005, 24(16):2599-2612. 10.1038/sj.onc.1208326, 15735756.
33. Rybin VO, Xu X, Lisanti MP, Steinberg SF. Differential targeting of beta -adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae. A mechanism to functionally regulate the cAMP signaling pathway. J Biol Chem 2000, 275(52):41447-41457. 10.1074/jbc.M006951200, 11006286.
34. Cho CH, Lee CS, Chang M, Jang IH, Kim SJ, Hwang I, Ryu SH, Lee CO, Koh GY. Localization of VEGFR-2 and PLD2 in endothelial caveolae is involved in VEGF-induced phosphorylation of MEK and ERK. Am J Physiol Heart Circ Physiol 2004, 286(5):H1881-H1888. 10.1152/ajpheart.00786.2003, 14704231.
35. Kendall RL, Rutledge RZ, Mao X, Tebben AJ, Hungate RW, Thomas KA. Vascular endothelial growth factor receptor KDR tyrosine kinase activity is increased by autophosphorylation of two activation loop tyrosine residues. J Biol Chem 1999, 274(10):6453-6460. 10.1074/jbc.274.10.6453, 10037737.
36. Takahashi T, Yamaguchi S, Chida K, Shibuya M. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J 2001, 20(11):2768-2778. 10.1093/emboj/20.11.2768, 125481, 11387210.
37. Park SY, Kang JH, Jeong KJ, Lee J, Han JW, Choi WS, Kim YK, Kang J, Park CG, Lee HY. Norepinephrine induces VEGF expression and angiogenesis by a hypoxia-inducible factor-1alpha protein-dependent mechanism. Int J Cancer 2011, 128(10):2306-2316. 10.1002/ijc.25589, 20715173.
38. Yang EV, Sood AK, Chen M, Li Y, Eubank TD, Marsh CB, Jewell S, Flavahan NA, Morrison C, Yeh PE, et al. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res 2006, 66(21):10357-10364. 10.1158/0008-5472.CAN-06-2496, 17079456.
39. Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel MA, Tangkanangnukul V, Arevalo JM, Morizono K, Karanikolas BD, Wu L, et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 2010, 70(18):7042-7052. 10.1158/0008-5472.CAN-10-0522, 2940980, 20823155.
40. Wu WK, Wong HP, Luo SW, Chan K, Huang FY, Hui MK, Lam EK, Shin VY, Ye YN, Yang YH, et al. 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone from cigarette smoke stimulates colon cancer growth via beta-adrenoceptors. Cancer Res 2005, 65(12):5272-5277. 10.1158/0008-5472.CAN-05-0205, 15958573.
41. Wong HP, Yu L, Lam EK, Tai EK, Wu WK, Cho CH. Nicotine promotes cell proliferation via alpha7-nicotinic acetylcholine receptor and catecholamine-synthesizing enzymes-mediated pathway in human colon adenocarcinoma HT-29 cells. Toxicol Appl Pharmacol 2007, 221(3):261-267. 10.1016/j.taap.2007.04.002, 17498763.
42. Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: a population- based study. J Clin Oncol 2011, 29(19):2635-2644. 10.1200/JCO.2010.33.5422, 21632503.
43. Powe DG, Voss MJ, Zanker KS, Habashy HO, Green AR, Ellis IO, Entschladen F. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 2010, 1(7):628-638. 3248123, 21317458.
44. Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN, Gonzalez-Angulo AM. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 2011, 29(19):2645-2652. 10.1200/JCO.2010.33.4441, 3139371, 21632501.
45. De Giorgi V, Grazzini M, Gandini S, Benemei S, Lotti T, Marchionni N, Geppetti P. Treatment with beta-blockers and reduced disease progression in patients with thick melanoma. Arch Intern Med 2011, 171(8):779-781. 10.1001/archinternmed.2011.131, 21518948.
46. Lemeshow S, Sorensen HT, Phillips G, Yang EV, Antonsen S, Riis AH, Lesinski GB, Jackson R, Glaser R. beta-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study. Cancer Epidemiol Biomarkers Prev 2011, 20(10):2273-2279. 10.1158/1055-9965.EPI-11-0249, 21933972.
47. Dosanjh A, Chang J, Bresnick S, Zhou L, Reinisch J, Longaker M, Karasek M. In vitro characteristics of neonatal hemangioma endothelial cells: similarities and differences between normal neonatal and fetal endothelial cells. J Cutan Pathol 2000, 27(9):441-450. 10.1034/j.1600-0560.2000.027009441.x, 11028814.
48. Yu Y, Varughese J, Brown LF, Mulliken JB, Bischoff J. Increased Tie2 expression, enhanced response to angiopoietin-1, and dysregulated angiopoietin-2 expression in hemangioma-derived endothelial cells. Am J Pathol 2001, 159(6):2271-2280. 10.1016/S0002-9440(10)63077-5, 1850579, 11733376.
49. Mayer M, Minichmayr A, Klement F, Hroncek K, Wertaschnigg D, Arzt W, Wiesinger-Eidenberger G, Lechner E. Tocolysis with the beta-2-sympathomimetic hexoprenaline increases occurrence of infantile haemangioma in preterm infants. Arch Dis Child Fetal Neonatal Ed 2012, In press.
50. Smith C, Teitler M. Beta-blocker selectivity at cloned human beta 1- and beta 2-adrenergic receptors. Cardiovasc Drugs Ther 1999, 13(2):123-126. 10.1023/A:1007784109255, 10372227.
51. Alhaja E, Adan J, Pagan R, Mitjans F, Cascallo M, Rodriguez M, Noe V, Ciudad CJ, Mazo A, Vilaro S, et al. Anti-migratory and anti-angiogenic effect of p16: a novel localization at membrane ruffles and lamellipodia in endothelial cells. Angiogenesis 2004, 7(4):323-333. 10.1007/s10456-005-0368-9, 15886876.
52. Ciccarelli M, Sorriento D, Cipolletta E, Santulli G, Fusco A, Zhou RH, Eckhart AD, Peppel K, Koch WJ, Trimarco B, et al. Impaired neoangiogenesis in beta(2)-adrenoceptor gene-deficient mice: restoration by intravascular human beta(2)-adrenoceptor gene transfer and role of NFkappaB and CREB transcription factors. Br J Pharmacol 2011, 162(3):712-721. 10.1111/j.1476-5381.2010.01078.x, 3041259, 20958287.
53. Steinle JJ, Cappocia FJ, Jiang Y. Beta-adrenergic receptor regulation of growth factor protein levels in human choroidal endothelial cells. Growth Factors 2008, 26(6):325-330. 10.1080/08977190802442070, 19021032.
54. Seya Y, Fukuda T, Isobe K, Kawakami Y, Takekoshi K. Effect of norepinephrine on RhoA, MAP kinase, proliferation and VEGF expression in human umbilical vein endothelial cells. Eur J Pharmacol 2006, 553(1-3):54-60.
55. Tilan J, Kitlinska J. Sympathetic neurotransmitters and tumor angiogenesis-link between stress and cancer progression. J Oncol 2010, 2010:539706. 2874925, 20508839.
56. Annabi B, Lachambre MP, Plouffe K, Moumdjian R, Beliveau R. Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion. Pharmacol Res 2009, 60(5):438-445. 10.1016/j.phrs.2009.05.005, 19467330.
57. Schuller HM, Al-Wadei HA, Ullah MF, Plummer HR. Regulation of pancreatic cancer by neuropsychological stress responses: a novel target for intervention. Carcinogenesis 2012, 33(1):191-196. 10.1093/carcin/bgr251, 3276326, 22072614.